48.71
-0.16(-0.33%)
Currency In USD
| Previous Close | 48.87 |
| Open | 48.91 |
| Day High | 49.61 |
| Day Low | 48.56 |
| 52-Week High | 54.18 |
| 52-Week Low | 24.1 |
| Volume | 273,535 |
| Average Volume | 1.56M |
| Market Cap | 4.62B |
| PE | -10.75 |
| EPS | -4.53 |
| Moving Average 50 Days | 44.47 |
| Moving Average 200 Days | 35.46 |
| Change | -0.16 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,987.35 as of December 25, 2025 at a share price of $48.71. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $3,651.42 as of December 25, 2025 at a share price of $48.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 9:05 PM GMT
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44th Annual J.P. Morgan Healthcare
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
GlobeNewswire Inc.
Dec 11, 2025 9:05 PM GMT
Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical measures of CAHSAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announce
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Dec 10, 2025 9:34 PM GMT
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ag